SCHEMBL5706356

SCHEMBL5706356

O=S(=O)(C(F)F)N(c1ccc(Cl)cn1)S(=O)(=O)C(F)F

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.39
NFE2L2 Q16236 6/20 0.35
FDPS P14324 1/20 0.35
FDFT1 P37268 1/20 0.35
POLB P06746 1/20 0.34
KDM4E B2RXH2 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
USP2 O75604 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
APLNR P35414 1/20 0.32
PTK2 Q05397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17322362 0.77 NFE2L2 (0.38) HDAC6NFE2L2POLBKDM4EL3MBTL1
SCHEMBL29377776 0.76 NFE2L2 (0.36) HDAC6NFE2L2POLBKDM4EL3MBTL1
SCHEMBL69571 0.76 NFE2L2 (0.36) HDAC6NFE2L2POLBKDM4EL3MBTL1
SCHEMBL15944537 0.71 NFE2L2 (0.33) HDAC6NFE2L2POLBKDM4EL3MBTL1
SCHEMBL15334372 0.68 NFE2L2 (0.34) HDAC6NFE2L2POLBKDM4EL3MBTL1
SCHEMBL7642605 0.66 POLB (0.35) HDAC6NFE2L2POLBKDM4EL3MBTL1
SCHEMBL19102454 0.65 ADRA2A (0.41) FDPSFDFT1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL16838713 0.65 ADK (0.43) L3MBTL1PTK2
SCHEMBL14339841 0.64 PTK2 (0.39) HDAC6NFE2L2FDPSFDFT1L3MBTL1
SCHEMBL28028214 0.62 ADRA2A (0.35) NFE2L2FDPSFDFT1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1696899-A1 METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B ALLERGAN, INC. (US) 2006-09-06 EP disclosed
WO-2005058301-A1 METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B ALLERGAN, INC. (US) 2005-06-30 WO disclosed